Published • loading... • Updated
Pfizer Announces Chief Financial Officer Transition
The company said it will search internally and externally for a permanent successor as investors question its 2026 forecast and obesity drug strategy.
- Pfizer announced on Thursday that CFO Dave Denton will leave on August 15 to return to the consumer goods industry, with Cecile Guegan named interim chief financial officer.
- Denton joined Pfizer in 2022, overseeing an aggressive dealmaking phase that utilized COVID-19 vaccine revenue to acquire Seagen, Biohaven, and Metsera to offset declining sales.
- CEO Albert Bourla has set a goal of adding $20 billion in revenue by 2030, though the company's shares have nearly halved since Denton took over as CFO.
- Scotiabank analyst Louise Chen noted that Denton's exit raises concerns among investors about the company's 2026 forecast and succession plans as Pfizer prepares to enter the obesity drug market.
- Guegan, who has held various finance roles at Pfizer over 20 years, will lead the department while the company conducts a comprehensive internal and external search for a permanent successor.
Insights by Ground AI
11 Articles
11 Articles
Cecile Guegan, current senior vice president of finance of the company's global biopharmaceutical business, will assume the role of interim financial director from August 16
·Brazil
Read Full Article
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources11
Leaning Left1Leaning Right2Center4Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
14%
C 57%
R 29%
Factuality
To view factuality data please Upgrade to Premium
